Table 1.
Patient characteristics and QoL scale scores at randomisation
| CMR-guided care (n=481) | SPECT-guided care (n=481) | NICE CG95 (2010) (n=240) | Total (n=1202) | |
| Patient age (years), mean (SD) | 56.5 (9.10) | 55.9 (8.87) | 56.5 (9.21) | 56.3 (9.03) |
| Male | 254 (52.8%) | 256 (53.2%) | 128 (53.3%) | 638 (53.1%) |
| White | 443 (92.1%) | 443 (92.1%) | 221 (92.1%) | 1107 (92.1%) |
| Current smoker | 123 (25.6%) | 106 (22.0%) | 65 (27.1%) | 294 (24.5%) |
| Diabetic: type II | 48 (10.0%) | 64 (13.3%) | 21 (8.8%) | 133 (11.1%) |
| Hypertension | 177 (36.8%) | 182 (37.8%) | 99 (41.3%) | 458 (38.1%) |
| Family history of premature CHD | 252 (52.4%) | 259 (53.8%) | 140 (58.3%) | 651 (54.2%) |
| Body mass index, mean (SD) | 29.2 (5.36) | 29.1 (5.12) | 29.0 (5.24) | 29.1 (5.23) |
| Duke clinical PTL category (as randomised) | ||||
| 10%–29% | 128 (26.6%) | 125 (26.0%) | 61 (25.4%) | 314 (26.1%) |
| 30%–60% | 179 (37.2%) | 183 (38.0%) | 88 (36.7%) | 450 (37.4%) |
| 61%–90% | 174 (36.2%) | 173 (36.0%) | 91 (37.9%) | 438 (36.4%) |
| Duke clinical PTL % (as analysed), mean (SD) | 49.9 (24.25) | 48.6 (23.57) | 50.7 (23.28) | 49.5 (23.78) |
| Baseline medication use | ||||
| Beta-blockers | 150 (31.2%) | 157 (32.6%) | 74 (30.8%) | 381 (31.7%) |
| Statins or other lipid-lowering medications | 191 (39.7%) | 201 (41.8%) | 108 (45.0%) | 500 (41.6%) |
| ACE inhibitor or angiotensin II receptor blocker | 115 (23.9%) | 122 (25.4%) | 66 (27.5%) | 303 (25.2%) |
| Antiplatelet agents | 271 (56.3%) | 268 (55.7%) | 150 (62.5%) | 689 (57.3%) |
| Other antianginal agents | 283 (58.8%) | 276 (57.4%) | 142 (59.2%) | 701 (58.3%) |
| SAQ-UK Angina Frequency score* | 70.0 (50.0–80.0) | 70.0 (60.0–80.0) | 70.0 (50.0–80.0) | 70.0 (50.0–80.0) |
| SAQ-UK Angina Stability score* | 50.0 (25.0–50.0) | 50.0 (25.0–50.0) | 50.0 (25.0–50.0) | 50.0 (25.0–50.0) |
| SAQ-UK Physical Limitation score* | 77.8 (58.3–91.7) | 75.0 (58.3–88.9) | 77.8 (55.6–88.9) | 77.8 (58.3–91.7) |
| SAQ-UK Quality of Life score* | 50.0 (41.7–66.7) | 50.0 (41.7–66.7) | 50.0 (33.3–66.7) | 50.0 (37.5–66.7) |
| SAQ-UK Treatment Satisfaction score* | 100.0 (81.3–100.0) | 100.0 (81.3–100.0) | 93.8 (81.3–100.0) | 100.0 (81.3–100.0) |
| SF12v2 Bodily Pain score† | 75.0 (50.0–75.0) | 75.0 (50.0–75.0) | 75.0 (50.0–75.0) | 75.0 (50.0–75.0) |
| SF12v2 General Health score† | 60.0 (25.0–60.0) | 60.0 (25.0–60.0) | 60.0 (25.0–60.0) | 60.0 (25.0–60.0) |
| SF12v2 Mental Health score† | 62.5 (50.0–75.0) | 62.5 (50.0–75.0) | 62.5 (50.0–75.0) | 62.5 (50.0–75.0) |
| SF12v2 Physical Function score† | 50.0 (50.0–91.1) | 50.0 (45.0–75.0) | 50.0 (50.0–75.0) | 50.0 (50.0–75.0) |
| SF12v2 Role Emotional score† | 87.5 (62.5–100.0) | 87.5 (50.0–100.0) | 75.0 (50.0–100.0) | 87.5 (62.5–100.0) |
| SF12v2 Role Performance score† | 62.5 (50.0–87.5) | 62.5 (50.0–75.0) | 62.5 (50.0–87.5) | 62.5 (50.0–78.9) |
| SF12v2 Social Functioning score† | 75.0 (50.0–100.0) | 75.0 (50.0–100.0) | 75.0 (50.0–100.0) | 75.0 (50.0–100.0) |
| SF12v2 Vitality score† | 50.0 (25.0–75.0) | 50.0 (25.0–75.0) | 50.0 (25.0–75.0) | 50.0 (25.0–75.0) |
| SF12v2 Physical Component score† | 45.2 (37.4–51.7) | 44.6 (37.8–50.9) | 43.9 (38.5–51.4) | 44.6 (37.8– 51.4) |
| SF12v2 Mental Component score† | 50.7 (43.3–57.3) | 50.5 (41.6–56.8) | 49.6 (40.8–56.7) | 50.5 (41.9–56.9) |
| EQ-5D-3L Utility‡ | 0.796 (0.691–0.883) | 0.760 (0.689–0.848) | 0.743 (0.656–0.883) | 0.760 (0.689–0.850) |
| EQ-5D-5L Utility‡ | 0.879 (0.778–0.937) | 0.859 (0.777–0.937) | 0.859 (0.733–0.937) | 0.861 (0.777–0.937) |
Values are n (%), except where mean (SD) are stated and for the SAQ-UK, SF12v2 and EQ-5D values, for which median (lower quartile–upper quartile) are given. Further baseline characteristics are given in Greenwood et al.5
*Baseline SAQ reported by 1187 (99%) of 1202 patients.
†Baseline SF12 reported by 1192 (99%) of 1202 patients.
‡ED-5D baseline reported by 1168 (97%) of 1202 patients.
CHD, coronary heart disease; CMR, cardiovascular magnetic resonance; EQ-5D, EuroQol-5 Dimension Questionnaire; NICE, National Institute for Health and Care Excellence; PTL, pretest likelihood; QoL, quality of life; SAQ, Seattle Angina Questionnaire; SF12v2, Short Form 12 (V.12) Questionnaire; SPECT, single-photon emission computed tomography.